{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T13:56:01Z","timestamp":1789826161906,"version":"4.0.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Burns"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.burns.2021.08.009","type":"journal-article","created":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T11:40:41Z","timestamp":1629286841000},"page":"1561-1573","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Review of culprit drugs associated with patients admitted to the burn unit with the diagnosis of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Syndrome"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0776-4882","authenticated-orcid":false,"given":"Paul","family":"de Bustros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Baldea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Sanford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0468-8271","authenticated-orcid":false,"given":"Cara","family":"Joyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5608-3808","authenticated-orcid":false,"given":"William","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Bouchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"January\u2013February (1)","key":"10.1016\/j.burns.2021.08.009_bib0005","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jaip.2017.11.023","article-title":"SJS\/TEN 2017: building multidisciplinary networks to drive science and translation","volume":"6","author":"White","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.burns.2021.08.009_bib0010","series-title":"StatPearls","article-title":"Stevens Johnson Syndrome","author":"Oakley","year":"2020"},{"issue":"November (Suppl 11)","key":"10.1016\/j.burns.2021.08.009_bib0015","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.1097\/ICO.0000000000000605","article-title":"Genetic predisposition to Stevens-Johnson Syndrome with severe ocular surface complications","volume":"34","author":"Ueta","year":"2015","journal-title":"Cornea"},{"issue":"August (2)","key":"10.1016\/j.burns.2021.08.009_bib0020","article-title":"Toxic epidermal necrolysis: part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment","volume":"69","author":"Schwartz","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"July (1)","key":"10.1016\/j.burns.2021.08.009_bib0025","first-page":"6","article-title":"Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"135","author":"Rzany","year":"1996","journal-title":"Br J Dermatol"},{"issue":"March (3)","key":"10.1016\/j.burns.2021.08.009_bib0030","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0190-9622(84)80090-0","article-title":"Erythema multiforme: clinical, histopathologic, and immunologic study","volume":"10","author":"Howland","year":"1984","journal-title":"J Am Acad Dermatol"},{"issue":"February (2)","key":"10.1016\/j.burns.2021.08.009_bib0035","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/ijd.14544","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis - retrospective review of cases in a high complexity hospital in Brazil","volume":"59","author":"Medeiros","year":"2020","journal-title":"Int J Dermatol"},{"issue":"November (11)","key":"10.1016\/j.burns.2021.08.009_bib0040","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.amjmed.2016.03.022","article-title":"Stevens-Johnson Syndrome and toxic epidermal necrolysis: an analysis of triggers and implications for improving prevention","volume":"129","author":"Miliszewski","year":"2016","journal-title":"Am J Med"},{"issue":"May\u2013June (3)","key":"10.1016\/j.burns.2021.08.009_bib0045","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1590\/abd1806-4841.20175171","article-title":"Severe cutaneous adverse drug reactions of Chinese inpatients: a meta-analysis","volume":"92","author":"Deng","year":"2017","journal-title":"An Bras Dermatol"},{"issue":"January (1)","key":"10.1016\/j.burns.2021.08.009_bib0050","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol"},{"issue":"January (1)","key":"10.1016\/j.burns.2021.08.009_bib0055","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.alit.2015.09.001","article-title":"Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients\u2014treatment and outcome","volume":"65","author":"Yamane","year":"2016","journal-title":"Allergol Int"},{"issue":"February (2)","key":"10.1016\/j.burns.2021.08.009_bib0060","article-title":"Searching for the culprit drugs for Stevens-Johnson Syndrome and toxic epidermal necrolysis from a nationwide claim database in Korea","volume":"8","author":"Yang","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"April (2)","key":"10.1016\/j.burns.2021.08.009_bib0065","first-page":"73","article-title":"A 10-years retrospective study on Severe Cutaneous Adverse Reactions (SCARs) in a tertiary hospital in Penang, Malaysia","volume":"73","author":"Loo","year":"2018","journal-title":"Med J Malaysia"},{"issue":"11","key":"10.1016\/j.burns.2021.08.009_bib0070","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1016\/j.jid.2018.04.027","article-title":"Stevens-Johnson Syndrome\/toxic epidermal necrolysis: a multicenter retrospective study of 377 adult patients from the United States","volume":"138","author":"Micheletti","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"September","key":"10.1016\/j.burns.2021.08.009_bib0075","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/jdv.16924","article-title":"The risk of anti-osteoporotic agent-induced severe cutaneous adverse drug reactions and their association with HLA","volume":"35","author":"Chen","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"August","key":"10.1016\/j.burns.2021.08.009_bib0080","article-title":"Systematic review of BRAF\/MEK inhibitors-induced Severe Cutaneous Adverse Reactions (SCARs)","author":"Torres-Navarro","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"April (4)","key":"10.1016\/j.burns.2021.08.009_bib0085","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/1744666X.2020.1740591","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: risk factors, causality assessment and potential prevention strategies","volume":"16","author":"Lin","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.burns.2021.08.009_bib0090","series-title":"NATIENS synopsis","author":"Phillips","year":"2020"},{"issue":"July (7)","key":"10.1016\/j.burns.2021.08.009_bib0095","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.jid.2016.03.023","article-title":"Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States adults","volume":"136","author":"Hsu","year":"2016","journal-title":"J Invest Dermatol"},{"issue":"December (12)","key":"10.1016\/j.burns.2021.08.009_bib0100","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/nm.1884","article-title":"Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"14","author":"Chung","year":"2008","journal-title":"Nat Med"},{"issue":"December (12)","key":"10.1016\/j.burns.2021.08.009_bib0105","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1136\/annrheumdis-2014-205577","article-title":"Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin","volume":"74","author":"Chung","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"May (5)","key":"10.1016\/j.burns.2021.08.009_bib0110","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.jid.2016.11.034","article-title":"Interleukin-15 is associated with severity and mortality in Stevens-Johnson Syndrome\/toxic epidermal necrolysis","volume":"137","author":"Su","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"April (1)","key":"10.1016\/j.burns.2021.08.009_bib0115","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jdermsci.2020.02.003","article-title":"SJS\/TEN 2019: from science to translation","volume":"98","author":"Chang","year":"2020","journal-title":"J Dermatol Sci"},{"issue":"February (6)","key":"10.1016\/j.burns.2021.08.009_bib0120","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"HLA-B*5701 screening for hypersensitivity to abacavir","volume":"358","author":"Mallal","year":"2008","journal-title":"N Engl J Med"},{"issue":"March (12)","key":"10.1016\/j.burns.2021.08.009_bib0125","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1056\/NEJMoa1009717","article-title":"Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan","volume":"364","author":"Chen","year":"2011","journal-title":"N Engl J Med"},{"issue":"October (17)","key":"10.1016\/j.burns.2021.08.009_bib0130","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1056\/NEJMoa1213096","article-title":"HLA-B*13:01 and the dapsone hypersensitivity syndrome","volume":"369","author":"Zhang","year":"2013","journal-title":"N Engl J Med"},{"issue":"September","key":"10.1016\/j.burns.2021.08.009_bib0135","doi-asserted-by":"crossref","first-page":"h4848","DOI":"10.1136\/bmj.h4848","article-title":"Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study","volume":"351","author":"Ko","year":"2015","journal-title":"BMJ"},{"issue":"March (3)","key":"10.1016\/j.burns.2021.08.009_bib0140","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/1744666X.2020.1729128","article-title":"Stevens-Johnson syndrome\/toxic epidermal necrolysis with severe ocular complications","volume":"16","author":"Ueta","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"issue":"April (6982)","key":"10.1016\/j.burns.2021.08.009_bib0145","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","article-title":"Medical genetics: a marker for Stevens-Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"issue":"December (12)","key":"10.1016\/j.burns.2021.08.009_bib0150","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1111\/j.1528-1167.2008.01719.x","article-title":"Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population","volume":"49","author":"Locharernkul","year":"2008","journal-title":"Epilepsia"},{"issue":"March (5)","key":"10.1016\/j.burns.2021.08.009_bib0155","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/hmg\/ddq537","article-title":"Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population","volume":"20","author":"Ozeki","year":"2011","journal-title":"Hum Mol Genet"},{"issue":"March (12)","key":"10.1016\/j.burns.2021.08.009_bib0160","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJMoa1013297","article-title":"HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans","volume":"364","author":"McCormack","year":"2011","journal-title":"N Engl J Med"},{"issue":"March (11)","key":"10.1016\/j.burns.2021.08.009_bib0165","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"February (2)","key":"10.1016\/j.burns.2021.08.009_bib0170","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/FPC.0b013e3282f3ef9c","article-title":"A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs","volume":"18","author":"Lonjou","year":"2008","journal-title":"Pharmacogenet Genomics"},{"issue":"February (1)","key":"10.1016\/j.burns.2021.08.009_bib0175","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/tpj.2011.41","article-title":"A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients","volume":"13","author":"Tohkin","year":"2013","journal-title":"Pharmacogenomics J"},{"issue":"July\u2013August (4)","key":"10.1016\/j.burns.2021.08.009_bib0180","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/sj.tpj.6500356","article-title":"A marker for Stevens-Johnson syndrome \u2026: ethnicity matters","volume":"6","author":"Lonjou","year":"2006","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.burns.2021.08.009_bib0185","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3389\/fphar.2019.00149","article-title":"A screening test for","volume":"10","author":"Fang","year":"2019","journal-title":"Front Pharmacol"},{"issue":"August (2)","key":"10.1016\/j.burns.2021.08.009_bib0190","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jaci.2015.05.050","article-title":"Evolving models of the immunopathogenesis of T cell-mediated drug allergy: the role of host, pathogens, and drug response","volume":"136","author":"White","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.burns.2021.08.009_bib0195","doi-asserted-by":"crossref","DOI":"10.1177\/2040622319894469","article-title":"Multidisciplinary care in Stevens-Johnson syndrome","volume":"11","author":"Shanbhag","year":"2020","journal-title":"Ther Adv Chronic Dis"},{"issue":"June (4)","key":"10.1016\/j.burns.2021.08.009_bib0200","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/jbcr\/irx016","article-title":"How does SCORTEN score?","volume":"39","author":"Zavala","year":"2018","journal-title":"J Burn Care Res"},{"issue":"November (5)","key":"10.1016\/j.burns.2021.08.009_bib0205","article-title":"Treatment of toxic epidermal necrolysis in North America","volume":"73","author":"Dodiuk-Gad","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"June (6)","key":"10.1016\/j.burns.2021.08.009_bib0210","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1001\/jamadermatol.2016.5668","article-title":"Systemic immunomodulating therapies for Stevens-Johnson Syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"153","author":"Zimmermann","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"November (9140)","key":"10.1016\/j.burns.2021.08.009_bib0215","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/S0140-6736(98)02197-7","article-title":"Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis","volume":"352","author":"Wolkenstein","year":"1998","journal-title":"Lancet"},{"issue":"March (3)","key":"10.1016\/j.burns.2021.08.009_bib0220","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1172\/JCI93349","article-title":"Randomized, controlled trial of TNF-alpha antagonist in CTL-mediated severe cutaneous adverse reactions","volume":"128","author":"Wang","year":"2018","journal-title":"J Clin Invest"},{"issue":"45","key":"10.1016\/j.burns.2021.08.009_bib0225","doi-asserted-by":"crossref","first-page":"6852","DOI":"10.2174\/1381612822666160928125152","article-title":"Severe drug hypersensitivity reactions: clinical pattern, diagnosis, etiology and therapeutic options","volume":"22","author":"Paulmann","year":"2016","journal-title":"Curr Pharm Des"},{"issue":"July (1)","key":"10.1016\/j.burns.2021.08.009_bib0230","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis","volume":"88","author":"Sassolas","year":"2010","journal-title":"Clin Pharmacol Ther"},{"issue":"March (3)","key":"10.1016\/j.burns.2021.08.009_bib0235","first-page":"323","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?","volume":"136","author":"Garcia-Doval","year":"2000","journal-title":"Arch Dermatol"},{"issue":"June (6)","key":"10.1016\/j.burns.2021.08.009_bib0240","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.jaad.2011.09.029","article-title":"Toxic epidermal necrolysis: review of pathogenesis and management","volume":"66","author":"Downey","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"February (5)","key":"10.1016\/j.burns.2021.08.009_bib0245","article-title":"Bullous drug reactions","volume":"100","author":"Mockenhaupt","year":"2020","journal-title":"Acta Derm Venereol"},{"issue":"December (24)","key":"10.1016\/j.burns.2021.08.009_bib0250","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"333","author":"Roujeau","year":"1995","journal-title":"N Engl J Med"},{"issue":"March (3)","key":"10.1016\/j.burns.2021.08.009_bib0255","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/jdv.12392","article-title":"Mycoplasma pneumoniae-associated mucositis\u2014case report and systematic review of literature","volume":"29","author":"Vujic","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"October (10)","key":"10.1016\/j.burns.2021.08.009_bib0260","first-page":"740","article-title":"Mycoplasma pneumoniae and mucositis\u2014part of the Stevens-Johnson syndrome spectrum","volume":"10","author":"Meyer Sauteur","year":"2012","journal-title":"J Dtsch Dermatol Ges"},{"issue":"February (2)","key":"10.1016\/j.burns.2021.08.009_bib0265","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jaad.2014.06.026","article-title":"Mycoplasma pneumoniae-induced rash and mucositis as a syndrome distinct from Stevens-Johnson syndrome and erythema multiforme: a systematic review","volume":"72","author":"Canavan","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"September (5)","key":"10.1016\/j.burns.2021.08.009_bib0270","doi-asserted-by":"crossref","first-page":"709","DOI":"10.4168\/aair.2019.11.5.709","article-title":"Severe cutaneous adverse reactions to antiepileptic drugs: a nationwide registry-based study in Korea","volume":"11","author":"Park","year":"2019","journal-title":"Allergy Asthma Immunol Res"},{"issue":"August","key":"10.1016\/j.burns.2021.08.009_bib0275","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis associated with the use of macrolide antibiotics: a review of published cases","author":"Pej\u010di\u0107","year":"2020","journal-title":"Int J Dermatol"},{"issue":"June (2)","key":"10.1016\/j.burns.2021.08.009_bib0280","doi-asserted-by":"crossref","first-page":"64","DOI":"10.12793\/tcp.2019.27.2.64","article-title":"Antiepileptic drug-induced severe cutaneous adverse reactions and HLA alleles: a report of five cases with lymphocyte activation test","volume":"27","author":"Kim","year":"2019","journal-title":"Transl Clin Pharmacol"}],"container-title":["Burns"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305417921002205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305417921002205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T08:18:22Z","timestamp":1759652302000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305417921002205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":56,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0305417921002205"],"URL":"https:\/\/doi.org\/10.1016\/j.burns.2021.08.009","relation":{},"ISSN":["0305-4179"],"issn-type":[{"value":"0305-4179","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Review of culprit drugs associated with patients admitted to the burn unit with the diagnosis of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Syndrome","name":"articletitle","label":"Article Title"},{"value":"Burns","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.burns.2021.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd and ISBI. All rights reserved.","name":"copyright","label":"Copyright"}]}}